TRILEND PHARMACEUTICALS PRIVATE LIMITED

Balance Sheet as at 31-03-2021

| Particulars Note No. | | Current Year | Previous Year | |
|--|------------|--------------|---|--|
| EQUITY AND LIABILITIES | | | | |
| Shareholder's Funds | | | | |
| Share Capital | 2 | 1,000,000 | 1,000,000 | |
| Reserves and Surplus | 3 | (313,888) | (56,18) | |
| Non-Current Liabilities | | | | |
| Long Term Borrowings | 4 | 5,316,500 | 2,651,50 | |
| Other Long Term Liabilities | | | , | |
| Long Term Provisions | | | , | |
| Deferred Tax Liability | | | | |
| Current Liabilities | | | | |
| Short-Term Borrowings | 5 | . | | |
| Trade Payables | 6 | | 5,928 | |
| Other Current Liabilities | 7 | . 1 | 3/320 | |
| Short-Term Provisions | 8 | | | |
| Total | | 6,002,612 | 3,601,247 | |
| ASSETS | | | | |
| Non-Current Assets | | | | |
| Fixed Assets | 1 1 | i i | | |
| (i) Tangible assets | 1 1 | | 100000000000000000000000000000000000000 | |
| (ii) Intangible assets | | 3,500,000 | 3,500,000 | |
| (iii) Capital work-in-progress | | | | |
| (iv) Intangible assets under development | | 1,834,710 | | |
| Non-current investments | 1 1 | | | |
| Deferred Tax Assets | | | | |
| Long term loans and advances | 1 1 | • | | |
| Other non-current assets | | : | • | |
| Current Assets | | | • | |
| Secuirities & Deposits | 9 | | | |
| Inventories | 10 | - 1 | | |
| Trade receivables | 11 | | | |
| Cash and bank Balances | 12 | | | |
| Short-term loans and advances | 13 | 54,917 | 47,596 | |
| Other Current Asset | 14 | 288,272 | 53,551 | |
| Total | " - | 324,713 | | |
| 4,000 | 1 - | 6,002,612 | 3,601,247 | |

As per our report of even date

For

SIROIYA & CO

Chartered Accountant

(Siddharth Mahasuk Mem. No. 177400

Date. 29.11.2021 Place: Ahmedabad For and on behalf of

TRILEND PHARMACEUTICALS PVT LTD

AMIT THAKKAR

(Director)

BHARAT THAKKAR

(Director)

Place: Ahmedabad

TRILEND PHARMACEUTICALS PRIVATE LIMITED

STATEMENT OF PROFIT & LOSS FOR THE YEAR ENDED ON 31 " MARCH, 2021

| Sr. No | Particulars | Note No. | Current Year | Previous Year |
|--------|--|----------|--------------|---------------|
| | REVENUE: | | | |
| I | Revenue from operations | 15 | | • |
| П | Other Income | 16 | | |
| ш | Total Revenue (I +II) | l L | 7 • | |
| | EXPENSES: | 1 [| | |
| | a.) Purchase of Traded Goods | 17 | | • |
| | b.) Direct Expenses | 18 | | * |
| | c.) (increase)/Decrease in Inventories | 19 | | * |
| | d.) Employee Benefit Expenses | 20 | | • |
| | e.) Finance Cost | 21 | | • |
| | f.) Depreciation and Amortization Expenses | | * | |
| | g.) Other Expenses | 22 | 257,707.00 | 56,181.00 |
| TV . | Total Expenses | | 257,707.00 | 56,181.00 |
| 7 | Profit/(Loss) before exceptional and extraordinary items and | ! | | |
| | tax (III-IV) | l | (257,707.00) | (56,181.00) |
| VI | Exceptional Items | | | • |
| VII | Profit/(Loss) before extraordinary items and tax (V - VI) | 1 - | (257,707.00) | (56,181.00) |
| VIII | Extraordinary Items | 1 - | | |
| x | Profit/(Loss) before tax (VII - VIII) | ! F | (257,707.00) | (56,181.00) |
| r | Tax expense: | 1 - | , , , | |
| | (1) Current tax | 1 1 | | |
| | (2) Deferred tax | !! | | |
| | (3) Prior period Income Tax | | | • |
| KI . | Net Profit/(Loss) For the year (IX - X) | - | (257,707.00) | (56,181.00) |
| (| XVI. Earnings per Equity Share: | 1 – – | | |
| | (Basic & Diluted) | | (2.58) | (0.56) |

As per our report of even date

For

SIROIYA & CO Chartered Accountant

(Siddharth Mahasukhlal Siroiya)

Mem. No. 177400 Date. 29.11.2021 Place: Ahmedabad For and on behalf of TRILEND PHARMACEUTICALS PVT LTD

AMIT THAKKAR

(Director)

BHARAT THAKKAR (Director)

TRILEND PHARMACEUTICALS PVT LTD

Notes annexed to and forming part of the accounts For the year ended on 31st march, 2021

| L | Particular HARE CAPITAL | | nt Year Rs.) | | ous year Rs.) |
|-----------------|---|---------|----------------------------|---------|----------------------------|
| _ | uthorised: | | | | |
| | 00,000 Equity Shares of Rs. 10.00 each | | 2,000,000 | | 2,000,000 |
| c . | showlded 0 Bald | | 2,000,000 | | 2,000,000 |
| | ubscrided & Paid-up 0,000 Equity Shares of Rs. 10.00 each | | 1,000,000 | | 1,000,000 |
| | | | 1,000,000 | | 1,000,000 |
| D: | etails of shareholders holding more than % shares in the Company | | | | |
| | | Но | lding | Holding | |
| | | In Nos. | In% | In Nos | In % |
| A | MIT THAKKAR | | | | |
| | ARESH PATEL | 14000 | 14% | 13000 | 13% |
| | LPESH THAKKAR | 20000 | 20% | 20000 | 20% |
| | HARAT THAKKAR | 13000 | 13% | | * |
| | LPESH PATEL | 13000 | 13% | 14000 | 14% |
| | MIT PATEL | 10000 | 10% | 20000 | 20% |
| | IILAN THAKKAR | 10000 | 10% | | |
| | RAKASH THAKKAR | 10000 | 10% | 10000 | 10% |
| | IMESH THAKKAR | 10000 | 10% | 10000 | 10% |
| | ESERVES & SURPLUS | | • | 13000 | 13% |
| _ | rofit for the year | | 257,707.00) 313,888.00) | | (56,181.00) (56,181.00) |
| LC | DNG-TERM BORROWING | | | | (+ |
| | mit Thakkar | | 300,000.00 | | 300,000.00 |
| | LPESH PATEL | | 800,000.00 | | 600,000.00 |
| | naratkumar Thakaar IMESH THAKKAR | 1, | 040,000.00 | | 550,000.00 |
| | ARESH PATEL | | 300,000.00 | | 300,000.00 |
| | MIT PATEL | | 551,500.00 | | 901,500.00 |
| Ar | MITPATEL | | 325,000.00 316,500.00 | | |
| _ | | | 310,300.00 | | ,651,500.00 |
| SH | ORT-TERM BORROWING | | | | |
| TR | ADE PAYABLES | | | | |
| Pa | yable | | _ | | F 000 |
| | | | | | 5,928 5,928.00 |
| | | | | | |
| Su | indry Creditors for Trade | | | | |
| <u>Su</u> Cn | indry Creditors for Trade editors For Goods, Services and Expenses | | • | | |
| <u>Su</u> Cn | andry Creditors for Trade editors For Goods, Services and Expenses | - | | | • |
| Cn | editors For Goods, Services and Expenses | | · | | • |
| On On | editors For Goods, Services and Expenses THER CURRENT LIABILITIES | | - | | ÷ |
| O1 Du | THER CURRENT LIABILITIES uties & Taxes | _ | | | · |
| O1 Du | editors For Goods, Services and Expenses THER CURRENT LIABILITIES | | ÷ | | |

| 8 | SHORT-TERM PROVISIONS | | |
|-----|---|----------------------|---------------------------|
| 1 | Provision for Taxation | | |
| 2 | Unpaid Audit Fees | | |
| 3 | Unpaid Interest | | |
| 4 | Unpaid Professional Fees | | i i |
| | Unpaid Salary | | - 0 |
| | | | - |
| 9 | Securities & Deposits | | |
| | Godown Deposit (Harsh Champalal) | | |
| ; | Godown Deposit (Hamant Mehta) | | - |
| | | | |
| 3 | Godown Deposit (Mahendra Mohanraj) | • | |
| 4 | Godown Deposit (Pravin Champalal) | | |
| | _ | | |
| | Inventories (as taken, valued and certified by the management) | | |
| 1 | Finished Goods | | |
| | | | - |
| 1 | Trade receivables (Unsecured, Considered good, unless otherwise stated) | | |
| 1 | Sundry Debtors | | |
| | Trade receivables | | |
| | - · | • | - |
| | | • | • |
| 2 . | CASH & BANK BALANCES | | |
| (0) | Palanes to a . | | |
| (4) | Balances with Banks :- | | |
| | SARANGPUR NAGRIK CO OP BANK | 41,214.00 | 47,696.00 |
| (b) | Cash on hand | | 145000 P 3467 1340 P 3550 |
| | | 13,702.00 | • |
| | Total (a)+(b) | 54,916.00 | 47,696.00 |
| 1 | SHORT-TERM LOANS & ADVANCES | in the second second | |
| (a) | Advance given for material factory building | | |
| - | | 288,272 | 53,551 |
| - 7 | Other Current Assets | | ASSESSED SERVICES |
| | GST CREDIT | | |
| | | 324,713 | |
| | | 324,713 | |

| Sales | | |
|--|---------------|----------------|
| | | |
| | | <u> </u> |
| OTHER INCOME | | |
| Kasar | | |
| | | |
| Purchase of Traded Goods | 0 | |
| Purchase | | |
| | i | • |
| DIRECT EXPENSES | | |
| 1 Hel Hamali Expense | | |
| 2 Local Tempo Charges | 0 | - |
| 3 Packing Material Expense | | 920 |
| 4 Transport Charges | | |
| September 1990 - Control of Contr | | |
| (Increase)/Decrease in Inventories | | |
| 1 Inventories at the end of the year | | |
| 2 Inventories at the beginning of the year | 9 . €9 | = 1 |
| a mentioned at the deginning of the year | | - : |
| | | |
| EMPLOYEE BENEFIT EXPENSES | | |
| 1 Director Remuneration | | |
| 2 Salaries, Wages, Allowances & Bonus | - | |
| 3 Incentive | 2 | |
| 4 Staff Uniform | - | |
| 5 Staff Conveyance Office | | |
| 6 Staff Welfare Expenses | - | |
| | <u> </u> | |
| FINANCE COST | | |
| 1 Interest on Car Loan | | |
| 2 Bank Charges | - | |
| | | |
| OTHER EXPENSES | | |
| 1 Bank Charges | 200 | |
| Formation Expense | 53,551 | |
| Electricity Power Expense | 83,660 | |
| Project Consultancy Expense | 47,296 | |
| ROC Penalty Expense | 50,000 | |
| Structure Design Expense | 11,000 | |
| Water Test Expsense Other Expense | 12,000 | |
| Other Expense | 181 | 56,181. |
| | 257,707.00 | 56,181. |

| Particulars | As at 31 March, 2018 | As at 31 March, 2017 |
|--|-------------------------|----------------------|
| a) Weighted average number of equity shares for | Rs. | Rs. |
| Earnings Per Share computation | 100,000 | 100,000 |
| b) Net Profit/(Loss) as per Profit & Loss Account available for Equity Shareholders (In Rs) | (257,707) | (56,181 |
| c) Earnings Per Share | | (30,101 |

24 RELATED PARTY DISCLOSURE

Signature to Notes 1 to 27

For

SIROIYA & CO

Chartered Accountant

(Siddharth Mahasukhia Siralya Mem. No. 177400

Date. 29.11.2021 Place: Ahmedabad For and on behalf of

TRILEND PHARMACEUTICALS PVT LTD

AMIT THAKKAR BHARAT THAKKAR

(Director)

(Director)

Place: Ahmedabad

TRILEND PHARMACEUTICALS PVT LTD

NOTE 28: SIGNIFICANT ACCOUNTING POLICIES AND NOTES ON ACCOUNTS SIGNIFICANT ACCOUNTING POLICIES:

Basis of preparation of Financial Statements:

The Financial Statements have been prepared on historical cost convention and in accordance with mandatory accounting standards issued by the Institute of Chartered Accountants of India, normally accepted accounting principles and the provision of the Companies Act, 2013 following mercantile system of accounting as adopted consistently by the company. Accounting policies not specifically referred to otherwise are consistent and in consonance with generally accepted accounting principles. In applying the accounting policies, considerations have been given to prudence, substance over form and materiality.

2

The presentation of financial statement in conformity with the generally accepted accounting principles requires estimates and assumptions to be made that affect the reported amount of assets and liabilities on the date of the financial statements and disclosure relating to contingent liabilities as at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Difference between the actual result and estimates are recognised in the period in which the results are known/ materialised.

Fixed Assets:

Fixed Assets are stated at cost of acquisition. The Company capitalizes all costs relating to the acquisition and installation of fixed assets.

Depreciation:

Depreciation on fixed assets is provided under the straight line method over the useful lives of assets as prescribed under Part C of schedule II to the Companies Act 2013. Depreciation on Fixed Assets added/ disposed off during the year is provided on pro-rata basis.

5 Revenue Recognition:

All expenditure and income to the extent considered payable and receivable respectively are accounted for on accrual basis.

Preliminary Expenses:

The company has fully written off the preliminary expenses.

Taxes on Income:

Income Tax expense for the year comprises of current tax and deferred tax.

Deferred Tax: Deferred tax is recognized, on timing differences, being the difference between taxable income and accounting income that originate in one period and are capable of reversal in one or more subsequent periods. The deferred tax asset and deferred tax liability is calculated by applying tax rate and tax laws that have been enacted or substantively enacted by the Balance Sheet date. Deferred tax assets arising mainly on account of brought forward losses and unabsorbed depreciation under tax laws are recognized only if there is a virtual certainty of its realization, supported by convincing evidence according to the management's judgment to the future taxable incomes. At each balance sheet date, the carrying amounts of deferred tax assets are reviewed to reassure realization.

Retirement Benefits:

The company has not made any provision for reitrement benefits payable to the employees. The same is being accounted for as and when paid.

Foreign Currency Transactions:

Transactions in Foreign currency are accounted at exchange rate prevailing on the date of transaction. The out-standing are converted on the closing exchange rate as on 31-03-2017 and gain or loss due to Foreign Exchange Fluctuation is transferred to Profit & Loss Account.

10 Provision, Contingent Liabilities and Contingent Assets:

Provisions are recognized when the company has present obligation as a result of past events, for which it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made for the amount of the obligation. Contingent Liabilities are disclosed by way of notes to financial statements. Contingent Assets are neither recognized not disclosed in the financial statements. Provisional, Contingent Liabilities and Contingent Assets are reviewed at each balance sheet date.

11 Earnings per Share:

Basic earnings per share are calculated by dividing the net profit or loss for the period attributable to equity by the weighted average number of equity shares outstanding during the period. For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

12 Valuation of Inventory:

Inventories of Stock in Trade are stated 'at cost or net realizable value, whichever is lower'

TRILEND PHARMACEUTICALS PVT LTD OTHER NOTES ON ACCOUNTS AND STATUTORY INFORMATION:

- 1 Figures have been rounded off to nearest rupee and the figures pertaining to previous year have been regrouped wherever necessary to make them comparable with the figures of current year. (Figures in the brackets are in respect of the previous year.)
- In the opinion of the management, the current assets, loans and advances have a value on realisation in the ordinary course of business, at least equal to the amount at which they are stated in the Balance Sheet. The provision for depreciation and other known liabilities is adequate and not in excess of what is required. The balances of sundry creditors, sundry debtors and loans and advances are subject to confirmation from the respective parties.
- 3 In opinion of the management, there is no contingent liability as on the date of the Balance Sheet.
- 4 The company has adopted the accounting standard 22 "Accounting for taxes on income" issued by the Institute of Chartered Accountants of India.

The cumulative Deferred Tax Assets as on 31st March 2017 and as on 31st March 2016 has not been recognised in the books of the company as the Deferred tax assets arising mainly on account of brought forward losses and unabsorbed depreciation under tax laws are recognized only if there is a virtual certainty of its realization, supported by convincing evidence according to the management's judgment to the future taxable incomes. As on the date of the balance sheet, the company has not recognised the deferred tax assets.

5 Loans and Advances in the nature of loans given to subsidiaries and associates.

FRN NO.

144526W AHMEDABAD

-) The company has not given loans to subsidiaries and\or associates.
- 2) None of the loanees have made investments in shares of the company.
- 6 There are no non resident shareholders in the company, hence this point is not applicable.

7 Segment Reporting

Since there are no separate reportable segments as per Accounting Standard 17- "Segment Reporting" issued by the council of the ICAI. Hence disclosure as required under AS-17 "Segment Reporting" is not made by the company.

For

SIROIYA & CO

For and on behalf of

TRILEND PHARMACEUTICALS PVT LTD

Chartered Accountant

111 1 100

AMIT THAKKAR

(Director)

BHARAT THAKKAR

(Director)

(Siddharth Mahasukhlai Siroiya Mem. No. 177400

Date. 29.11.2021 Place: Ahmedabad

INDEPENDENT AUDITOR'S REPORT

To,
The Members of,
TRILEND PHARMACEUTICALS PVT LTD
AHMEDABAD.

1 Report on the Financial Statement

We have audited the accompanying financial statement of TRILEND PHARMACEUTICALS PVT LTD, which comprise the Balance Sheet as at March 31, 2021 and the Statement of Profit and Loss for the year then ended, and a summary of significant accounting policies and other explanatory statement.

2 Management's Responsibilty for the Financial Statements

The Companies Board of Directors is responsible for the matters in the section 134 (5) of the Compnies Act, 2013 (herein after reffered as an "the Act") with respect to the preperation of these financial statement that give true and fair view of the financial position, financial performance and cash flow of the company in accordance with the accounting principles generally accepted in India, Including Accounting Standard specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes the maintenance of adequate accounting records in accordance with the provision of the Act for safegaurding of the assets of the Company and for Preventing and detecting the frauds and other irreguralites, selection and application of appropriate accounting policies; making judgement and estimates that are reasonable and prudent; and design, implementation and maintenance of internal financial control, that were operating effectively for ensuring the accuracy and completness of the accounting records, relevant to the preperation and presentation of the financial statements that give a true and fair view an free from the material misstatemnt, whether due to fraud and error

3 Auditor's Responsibility

Our responsibility is to express an opinion on these financial statement based on our audit.

We have taken in to account the provision of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provision of the Act and the Rules made thereunder

We conducted our audit in accordance with the Standards of Auditing specified under Section 143(10) of the Act, Those Standards Required that we comply with ethical requirements and plan and perform the audit to obtain resonable assurance about whether the financial statement are free from material misstatement

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedure selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial

statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the financial statements in order to design audit procedured that are appropriate in the circumstances, but not for expressing an opinion on effectiveness on the entity's internal control system. An audit also includes evaluating the appropriateness of accounting policies used and the reasonbleness of the accounting estimates made by the management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

4 Opinion

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statement give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India:

- (1) In the case of the Balance Sheet, of the state of affairs of the Company as at 31st March, 2021: and
- (2) In the case of the Statement of Profit and Loss Account, of the profit for the year ended on that date.

5 Report on other Legal and Regulatory Requirements

- (I) As required by the Companies (Auditor's Report) order, 2016 (the order) issued by the Central Government of India in terms of sub-section (11) of the section 143 of the Companies Act,2013, since in our opinion and information and explanation given to us, the said order is no applicable to the company
- (II) As required by section 143(3) of the Act, we report that:
 - We have obtained all the information and explanations, which to the best of our knowledge (i) and belief were necessary for the purposes of our audit;
 - In our opinion, proper books of account as required by law have been kept by the Company (ii) so far as appears from our examination of those books;
 - (iii) The Balance Sheet and Statement of Profit and Loss Accounts, and Cash Flow Statement dealt with by this report are in agreement with the books of account;
 - (iv) In our opinion, the aforesaid financial statements are dealt with by this report comply with

the accounting standards specified under section 133 of the Act, read with Rule 7 of the companies (Accounts) Rules, 2014.

(v) On the basis of written representations received from the directors, as on 31st March, 2021, and taken on record by the Board of Directors, we report that none of the

Contd..... 3

directors is disqualified as on 31st March, 2020 from being appointed as a director in terms of Section 164 (2) of the Act.

- (vi) with respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "Annexure B"; and
- (vii) With respect to other matters included in the Auditor's Report and to our best of our information and according to the explanation given to us:
 - The Company has disclosed the impact of pending litigation on its financial position in its financial statements
 - 2) The company did not have any material forseable losses on long term contracts including derivative contracts
 - 3) There has been no amounts required to be transferred, to the Investor Education and Protection Fund.

For, SIROIYA & CO.

CHARTERED ACCOUNTANTS

SIDDHARTH MAHASUKHLAL SIROIYA

(Proprietor)

Membership No: 177400

Place : Ahmedabad

Date : 29.11.2021